Track Dianthus Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Dianthus Therapeutics Inc. Common Stock DNTH · Stock Open Dianthus Therapeutics Inc. Common Stock in new tab

91.81 USD
EPS
-4.08
P/B
4.05
ROE
-22.61
Beta
0.26
Target Price
139.25 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-4.08
Book Value22.05
Price to Book4.05
Debt/Equity0.10
% Insiders0.123%
Growth
Revenue Growth2.06%
Estimates
Forward P/E-20.53
Forward EPS-4.35
Target Mean Price139.25

DCF valuation

Model fair value for Dianthus Therapeutics Inc. Common Stock (DNTH)
Result
Sign in to run the valuation for DNTH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
16 analysts · consensus Strong buy · mean target 139.25 USD (low 113.00, high 200.00) · as of 12 Nov 2026
Low 113.00
Mean 139.25
High 200.00
Price 91.81
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Dianthus Therapeutics Inc. Common Stock Logo Dianthus Therapeutics Inc. Common Stock Analysis (DNTH)

United States Health Care Official Website Stock

Is Dianthus Therapeutics Inc. Common Stock a good investment? Dianthus Therapeutics Inc. Common Stock (DNTH) is currently trading at 91.81 USD. Market analysts have a consensus price target of 139.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: Dianthus Therapeutics Inc. Common Stock is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -4.35.

Investor FAQ

Does Dianthus Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Dianthus Therapeutics Inc. Common Stock?

Dianthus Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -4.08.

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Exchange Ticker
NMS (United States) DNTH
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 12, 2023 1:16
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion